Friday preview: US consumer confidence, AstraZeneca in focus
11th Nov 2021 14:15
(Sharecast News) - Financial markets' focus at the end of the week will shift back towards the US.
Read moreAstraZeneca offloads rights to Eklira and Duaklir
1st Nov 2021 07:40
(Sharecast News) - AstraZeneca has agreed to transfer its global rights to 'Eklira', or aclidinium bromide, and 'Duaklir', or aclidinium bromide with formoterol, to Covis Pharma Group, it announced on Monday.
Read moreJ.P.Morgan keeps AstraZeneca as 'top pick' on growth outlook, undervaluation
21st Oct 2021 11:21
(Sharecast News) - AstraZeneca's growth outlook is the best in its sector and was not yet reflected in its share price, analysts at JP Morgan said following a 'deep dive' into the drug maker's financials.
Read moreNovavax shares plummet on report of further delays in Covid-19 vaccine
20th Oct 2021 11:10
(Sharecast News) - Novavax's manufacturing problems may be more serious than previously thought and could hamper global efforts to fight Covid-19.
Read moreValneva vaccine 'outperforms' AstraZeneca shot in trial
18th Oct 2021 10:55
(Sharecast News) - A Covid-19 vaccine being developed by Valneva performed better than AstraZeneca's jab in trials, the French biotech announced on Monday, sending its shares soaring.
Read moreAstraZeneca tells investors to reject TRC Capital 'mini-tender' offer
18th Oct 2021 07:29
(Sharecast News) - Pharmaceutical giant AstraZeneca on Monday recommended shareholders of its American depositary shares reject a $115m 'mini-tender' offer from TRC Capital Investment, due to a low bid price.
Read moreAstraZeneca reports latest positive results from Imfinzi trials
15th Oct 2021 07:49
(Sharecast News) - AstraZeneca said on Friday that positive high-level results from the 'HIMALAYA' phase 3 trial showed a single, high priming dose of tremelimumab added to 'Imfinzi', or durvalumab. demonstrated a statistically-significant and clinically meaningful overall survival (OS) benefit for carcinomas associated with liver cancer.
Read moreAstraZeneca antibody cocktail shows reduced risk of Covid infection
11th Oct 2021 07:02
(Sharecast News) - AstraZeneca said its antibody cocktail to combat Covid-19 had achieved a "statistically significant reduction" in the risk of developing the virus or death in a phase 3 trial.
Read moreAstraZeneca seeks emergency approval for Covid antibody drug
5th Oct 2021 07:55
(Sharecast News) - AstraZeneca is seeking approval for a new Covid-19 treatment intended to help people who respond poorly to vaccines, the Anglo-Swedish drugs firm said on Tuesday.
Read moreAstraZeneca breast cancer drug wins US breakthrough therapy designation
4th Oct 2021 07:28
(Sharecast News) - AstraZeneca said its breast cancer drug Enhertu had been granted breakthrough therapy designation (BTD) in the US.
Read moreAstraZeneca to buy Caelum in $500m deal
29th Sep 2021 07:39
(Sharecast News) - AstraZeneca said on Wednesday that its newly-acquired Alexion business will buy the remaining shares of drug maker Caelum Biosciences for up to $500m.
Read moreAstraZeneca lupus drug gets approval in Japan
28th Sep 2021 08:01
(Sharecast News) - AstraZeneca said on Tuesday that its Saphnelo (anifrolumab) drug has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE).
Read moreAstraZeneca reports latest positive results for 'Lynparza'
24th Sep 2021 07:28
(Sharecast News) - AstraZeneca said on Friday that positive high-level results from the 'PROpel' phase 3 trial showed 'Lynparza', or olaparib, in combination with abiraterone, demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus standard-of-care abiraterone, as a first-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.
Read moreAstraZeneca planning new Dublin manufacturing facility
21st Sep 2021 07:41
(Sharecast News) - AstraZeneca said on Tuesday that it is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to secure its global supply network.
Read moreAstraZeneca upbeat on 'groundbreaking' Enhertu results
20th Sep 2021 07:29
(Sharecast News) - AstraZeneca said on Monday that detailed positive results from the head-to-head 'DESTINY-Breast03' phase 3 trial showed that Enhertu, or trastuzumab deruxtecan, demonstrated superior progression-free survival compared to trastuzumab emtansine (T-DM1).
Read more